Gilead Sciences, Inc. (GILD.SW)

Gilead Sciences, Inc. (GILD.SW) — VMCI valuation read

GILD.SW prints VMCI 50/100 inside the Healthcare sector, where the median sits at 50. The 1-point below-median delta is the cleanest single-number summary of Gilead Sciences, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On GILD.SW, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** GILD.SW trades at 22.0x earnings, 22% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 1.4x leaves covenant headroom; that is the risk line for Gilead Sciences, Inc. on the trailing financials.

GILD.SW rose 2.1% over the trailing 7 days, with a -6.7% read on a 30-day basis.